July 13, 2018 10:22 AM EDT
News Briefing

Tai­ho kicks off $130M Ar­cus deal with drug op­tion; J&J al­lies with Mer­ck KGaA to take di­a­betes drug to Chi­na

Brittany Meiling

→ Japan’s Tai­ho Phar­ma has de­cid­ed to go for an op­tion to de­vel­op and com­mer­cial­ize an adeno­sine re­cep­tor an­tag­o­nist pro­gram from Ar­cus Bio­sciences $RCUS, trig­ger­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times